האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunossupressores - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - imune soros e imunoglobulinas, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumores do estromal gastrointestinal - agentes antineoplásicos - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agentes antineoplásicos - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mieloma múltiplo - agentes antineoplásicos - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - infecções por citomegalovírus - antivirais para uso sistêmico - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes antivirais.

פורטוגל - פורטוגלית - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

tecnimede - sociedade técnico-medicinal, s.a. - buprenorfina - sistema transdérmico - 52.5 µg/h - buprenorfina 30 mg - buprenorphine - n/a - duração do tratamento: longa duração

פורטוגל - פורטוגלית - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - buprenorfina - comprimido sublingual - 0.4 mg - buprenorfina, cloridrato 0.43 mg - buprenorphine - genérico - duração do tratamento: longa duração

פורטוגל - פורטוגלית - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - buprenorfina - comprimido sublingual - 2 mg - buprenorfina, cloridrato 2.16 mg - buprenorphine - genérico - duração do tratamento: longa duração

פורטוגל - פורטוגלית - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - buprenorfina - comprimido sublingual - 8 mg - buprenorfina, cloridrato 8.64 mg - buprenorphine - genérico - duração do tratamento: longa duração